137 related articles for article (PubMed ID: 35842199)
21. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
Mitchell MS; Abrams J; Thompson JA; Kashani-Sabet M; DeConti RC; Hwu WJ; Atkins MB; Whitman E; Ernstoff MS; Haluska FG; Jakowatz JG; Das Gupta TK; Richards JM; Samlowski WE; Costanzi JJ; Aronson FR; Deisseroth AB; Dudek AZ; Jones VE
J Clin Oncol; 2007 May; 25(15):2078-85. PubMed ID: 17513813
[TBL] [Abstract][Full Text] [Related]
22. A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients.
Mao L; Si L; Chi Z; Cui C; Sheng X; Li S; Tang B; Guo J
Eur J Cancer; 2011 Jul; 47(10):1498-503. PubMed ID: 21493058
[TBL] [Abstract][Full Text] [Related]
23. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
Eggermont AM; Suciu S; Testori A; Santinami M; Kruit WH; Marsden J; Punt CJ; Salès F; Dummer R; Robert C; Schadendorf D; Patel PM; de Schaetzen G; Spatz A; Keilholz U
J Clin Oncol; 2012 Nov; 30(31):3810-8. PubMed ID: 23008300
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
[TBL] [Abstract][Full Text] [Related]
25. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.
Eggermont AMM; Kicinski M; Blank CU; Mandala M; Long GV; Atkinson V; Dalle S; Haydon A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Krepler C; Ibrahim N; Marreaud S; van Akkooi A; Robert C; Suciu S
JAMA Oncol; 2020 Apr; 6(4):519-527. PubMed ID: 31895407
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma.
Pectasides D; Dafni U; Bafaloukos D; Skarlos D; Polyzos A; Tsoutsos D; Kalofonos H; Fountzilas G; Panagiotou P; Kokkalis G; Papadopoulos O; Castana O; Papadopoulos S; Stavrinidis E; Vourli G; Ioannovich J; Gogas H
J Clin Oncol; 2009 Feb; 27(6):939-44. PubMed ID: 19139440
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy of adjuvant programmed cell death 1 (PD-1) monoclonal antibody immunotherapy in Chinese patients with resected stage Ⅱ-Ⅲ melanoma].
Ren ZG; Xu Y; Hua ZZ; Mo ZY; Wang LW; Shi GB; Liu WL; Sun W; Zheng BQ; Wang CM; Jin YJ; Chen Y
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):973-980. PubMed ID: 37968084
[No Abstract] [Full Text] [Related]
28. Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients With Advanced Melanoma.
Tang B; Duan R; Zhang X; Qin S; Wu D; Chen J; Yao H; Chi Z; Guo J; Yan X
Oncologist; 2024 Jun; 29(6):e822-e827. PubMed ID: 38547052
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Eggermont AMM; Blank CU; Mandalà M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C;
Lancet Oncol; 2021 May; 22(5):643-654. PubMed ID: 33857412
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
[TBL] [Abstract][Full Text] [Related]
31. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.
Kirkwood JM; Manola J; Ibrahim J; Sondak V; Ernstoff MS; Rao U;
Clin Cancer Res; 2004 Mar; 10(5):1670-7. PubMed ID: 15014018
[TBL] [Abstract][Full Text] [Related]
32. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H;
Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant Therapy for Melanoma.
Agha A; Tarhini AA
Curr Oncol Rep; 2017 May; 19(5):36. PubMed ID: 28417343
[TBL] [Abstract][Full Text] [Related]
34. Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial.
Tang B; Chi Z; Chen Y; Liu X; Wu D; Chen J; Song X; Wang W; Dong L; Song H; Wu H; Feng H; Yao S; Qin S; Zhang X; Guo J
Clin Cancer Res; 2020 Aug; 26(16):4250-4259. PubMed ID: 32321714
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma.
Tarhini AA; Moschos SJ; Lin Y; Lin HM; Sander C; Yin Y; Venhaus R; Gajewski TF; Kirkwood JM
Melanoma Res; 2017 Aug; 27(4):342-350. PubMed ID: 28489678
[TBL] [Abstract][Full Text] [Related]
36. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.
Schadendorf D; Luke JJ; Ascierto PA; Long GV; Rutkowski P; Khattak A; Del Vecchio M; de la Cruz-Merino L; Mackiewicz J; Sileni VC; Kirkwood JM; Robert C; Grob JJ; Dummer R; Carlino MS; Zhao Y; Kalabis M; Krepler C; Eggermont A; Scolyer RA
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485189
[TBL] [Abstract][Full Text] [Related]
37. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis.
Kleeberg UR; Suciu S; Bröcker EB; Ruiter DJ; Chartier C; Liénard D; Marsden J; Schadendorf D; Eggermont AM;
Eur J Cancer; 2004 Feb; 40(3):390-402. PubMed ID: 14746858
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma.
Najjar YG; McCurry D; Lin H; Lin Y; Zang Y; Davar D; Karunamurthy A; Drabick JJ; Neves RI; Butterfield LH; Ernstoff MS; Puzanov I; Skitzki JJ; Bordeaux J; Summit IB; Bender JO; Kim JY; Chen B; Sarikonda G; Pahuja A; Tsau J; Alfonso Z; Laing C; Pingpank JF; Holtzman MP; Sander C; Rose A; Zarour HM; Kirkwood JM; Tarhini AA
Clin Cancer Res; 2021 Aug; 27(15):4195-4204. PubMed ID: 33753453
[TBL] [Abstract][Full Text] [Related]
39. Feasibility of high-dose interferon-alpha2b adjuvant therapy for high-risk resected cutaneous melanoma.
Muggiano A; Mulas C; Fiori B; Liciardi G; Pintus M; Tanca L; Tedde A; Turno R; Desogus A
Melanoma Res; 2004 Apr; 14(2):S1-7. PubMed ID: 15057049
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
Livingstone E; Zimmer L; Hassel JC; Fluck M; Eigentler TK; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kiecker F; Dippel E; Roesch A; Ziemer M; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2022 Oct; 400(10358):1117-1129. PubMed ID: 36099927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
